LLY — Eli Lilly and Co Income Statement
0.000.00%
Last trade - 00:00
- $877.92bn
- $903.52bn
- $34.12bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 22,320 | 24,540 | 28,318 | 28,541 | 34,124 |
Cost of Revenue | |||||
Gross Profit | 17,598 | 19,057 | 21,006 | 21,912 | 27,042 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 17,288 | 18,482 | 22,367 | 21,414 | 27,666 |
Operating Profit | 5,032 | 6,058 | 5,952 | 7,127 | 6,458 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 5,266 | 7,230 | 6,156 | 6,806 | 6,555 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4,638 | 6,194 | 5,582 | 6,245 | 5,240 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 8,318 | 6,194 | 5,582 | 6,245 | 5,240 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 8,318 | 6,194 | 5,582 | 6,245 | 5,240 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 5.7 | 7.63 | 7.8 | 8.16 | 10.1 |
Dividends per Share |